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Abstract
Background: Substantial progress has been made in the medical management of rheumatoid arthritis (RA) over
the past decade with the introduction of biologic therapies, including anti-tumour necrosis factor alpha (anti-TNFa)
therapy medications. However, individuals with RA taking anti-TNFa medication continue to experience physical,
psychological and functional consequences, which could potentially benefit from rehabilitation. There is evidence
that therapeutic exercise should be included as an intervention for people with RA, but to date there is little
evidence of the benefits of therapeutic exercise for people with RA on anti-TNFa therapy medication. A protocol
for a multicentre randomised controlled three-armed study which aims to examine the effect of dynamic group
exercise therapy on land or in water for people with RA taking anti-TNFa therapy medication is described.
Methods/Design: Six hundred and eighteen individuals with RA, on anti-TNFa therapy medication, will be
randomised into one of 3 groups: a land-based exercise group; a water-based exercise group or a control group.
The land and water-based groups will exercise for one hour, twice a week for eight weeks. The control group will
receive no intervention and will be asked not to alter their exercise habits for the duration of the study. The
primary outcome measure, the Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) which
measures functional ability, and secondary measures of pain, fatigue and quality of life, will be assessed at baseline,
eight and 24 weeks by an independent assessor unaware of group allocation. Changes in outcome from 0 to 8
weeks and 0 to 24 weeks in the ‘land-based exercise group versus control group’ and the ‘water-based exercise
group versus control group’ will be examined. Analysis will be conducted on an intention to treat basis.
Discussion: This trial will evaluate the effectiveness of group exercise therapy on land or in water, for people with
RA taking anti-TNFa therapy medication. If these exercise groups are found to be beneficial, they could be
conducted in local community facilities thus making these forms of exercise more easily accessible for individuals
and potentially reduce the burden on health services.
Trial Registration: This trial is registered with ClinicalTrials.gov (a service of the United States National Institutes of
Health) identifier: NCT00855322.
Background
Rheumatoid arthritis (RA) is a chronic inflammatory,
autoimmune disease that leads to progressive joint
destruction and disability. It is estimated to affect in the
region of 1.16% of women and 0.44% of men in the UK
[1]. Arthritis Ireland reports that over 1 in 6 people cur-
rently have some form of arthritis in Ireland. It is pro-
jected that by 2031, the majority of the population will
be in the 50-54 age-bracket. The incidence of arthritis
increases with age and the peak incidence of conditions
like RA is the 50-55 year age group. Due to this preva-
lence of rheumatic conditions in older people, the inci-
dence of conditions such as RA will increase. * Correspondence: angelatreid@hotmail.com
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management of RA over the past decade. Biologic drugs
have been introduced including agents targeting tumour
necrosis factor alpha (TNFa). Among them, Infliximab,
Etanercept and Adalimumab have been shown in trials
to reduce signs and symptoms of RA and protect joints
from structural damage more effectively than conven-
tional disease modifying anti-rheumatic drugs [2]. As no
drug therapy at present leads to long-term remission for
all people with RA, some people continue to experience
physical, psychological and functional consequences,
which could potentially benefit from rehabilitation [3].
Exercise is an important non-pharmacological therapy
in RA [4].
Rheumatoid cachexia, the loss of muscle mass and
strength and concomitant increase in fat mass, is very
common in RA and may affect up to two-thirds of
patients [5]. It is also thought to be an important contri-
butor to increased morbidity and premature mortality in
RA [6]. Rheumatoid cachexia may be attributed to high
levels of TNFa [7]. There is evidence to suggest that, in
the short term, anti-TNFa therapy may improve pro-
cesses involved in the causation of rheumatoid cachexia,
including systemic inflammation and cytokine release
[8-10]. As a result of the reduced inflammatory activity
and cytokinin levels in individuals with RA taking anti-
TNFa medication, they may potentially be better posi-
tioned in terms of their available fat-free muscle mass to
benefit from an exercise intervention than individuals
not taking anti-TNFa therapy medication. It is possible
that as a result of taking anti-TNFa medication, their
baseline muscle quality may be better thereby increasing
the effectiveness of exercise over and above that seen in
individuals with RA not taking this medication. Poten-
tially, anti-TNFa therapy medication and exercise
together may be more effective than exercise alone, with
the possibility that one intervention may serve to
enhance the effectiveness of the other. However, to date
there is little evidence in relation to the effect of exer-
cise in people with RA currently taking anti-TNFa ther-
apy medication.
It has recently been recommended that promotion of
physical activity in older adults, and in adults aged 50 to
64 years with clinically significant chronic conditions,
should emphasise moderate intensity aerobic activity,
muscle strengthening activity and reducing sedentary
behaviour [11]. It has been suggested that there is a case
for recommendations supporting healthy physical activ-
ity behaviours among people with RA [12]. RA is asso-
ciated with an increased risk of cardiovascular disease
[13]. It has been recognised that women with RA are
twice as likely to develop heart disease than individuals
of similar age without RA, and are three times more
likely to have heart disease having been diagnosed with
RA for more than 10 years [14]. Therefore, general car-
diovascular fitness and hence exercise participation is
essential for this population.
In August 2006 an audit was undertaken of a phy-
siotherapy review service for people with RA attending a
biologic therapy outpatient clinic in a rheumatology
rehabilitation unit in Dublin, Ireland. The disease status
of these individuals was regarded by their consultant
rheumatologists as being stable and well controlled on
their anti-TNFa therapy medication. Previously these
patients were not routinely reviewed by a physiothera-
pist, yet musculoskeletal problems still arose despite
their RA being quiescent. Of the people who received
physiotherapy intervention (n = 30), 70% (n = 21)
required exercise prescription. This involved specific,
individual exercise programmes. Group exercise pro-
grammes may represent a means of encouraging struc-
tured, ongoing exercise therapy for this group of
patients.
The evidence for land-based exercise
Exercise is considered to be an important cornerstone of
the treatment of RA [15]. Exercise is physical activity that
is planned, structured, and repetitive, aimed at improving
or maintaining physical fitness [16]. A randomised con-
t r o l l e dt r i a l( R C T )b yV a nD e nE n d ee ta l[ 1 7 ]h i g h -
lighted that combining intense aerobic and resistance
training for individuals with RA can lead to significant
enhancement in aerobic capacity and muscular strength.
A trial of intensive exercise over two years by De Jong et
al [18] demonstrated significant improvements in func-
tional ability without detrimental effects on disease activ-
ity. Other randomised controlled trials support the
beneficial effects of exercise in individuals with early RA
with respect to muscle strength, aerobic capacity and
pain, but not for functional capacity and bone mineral
density [19-21]. Progressive resistance training may be an
effective and safe intervention for stimulating muscle
growth in people with RA [22]. Neuberger et al [23]
demonstrated that symptoms associated with RA, fatigue,
pain and reduced functional ability, were positively influ-
enced by a group exercise programme.
Systematic reviews have found that aerobic and
strengthening exercise lead to significant improvements
in physical and psychological status without exacerbat-
ing disease activity [15,24]. The Ottawa panel concluded
that good evidence exists that therapeutic exercise
should be included as an intervention for people with
RA [25]. Metsios et al [26] reported that there is strong
evidence suggesting that exercise from low to high
intensity of various modes is effective in improving dis-
ease-related characteristics and functional ability in peo-
ple with RA. Guidelines for the management of RA
support regular participation in dynamic and aerobic
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mobility, muscle strength, aerobic fitness and function,
and psychological well being [27], without, in the short-
term, exacerbating disease activity or joint destruction
[28]. Clinical practice guidelines by Gossec et al [29]
conclude that physical exercise and sports can be
recommended to people with early RA and that muscle
strength exercises are advisable. The European League
Against Rheumatism (EULAR) recommendations for the
management of early arthritis support the use of
dynamic exercises as a treatment adjunct to pharmaceu-
tical interventions [30].
In summary, therapeutic exercise has been found to be
beneficial for individuals with RA, however the value of
exercise for people with RA taking anti-TNFa therapy
medication has yet to be established.
The evidence for water-based exercise
Hydrotherapy involves exercising in warm water. The
combined effect of the warmth and buoyancy of the
water cause a reduction in joint loading, which results in
an increase in ease of movement, with less pain [31]. To
date, there have been few controlled trials examining
hydrotherapy intervention for people with RA. Two con-
trolled studies demonstrated that there was no negative
impact on disease activity post hydrotherapy intervention
[31,32]. Bilberg et al [33] found that moderate intensity
pool therapy significantly improved muscle endurance in
the upper and lower extremities in people with RA, but
had no impact on aerobic capacity. Another RCT, carried
out by Eversden et al [34], did not demonstrate any
improvement in functional scores, quality of life mea-
sures or pain scores following hydrotherapy treatment. A
Cochrane review of balneotherapy for people with RA, in
2003, concluded that positive findings were noted in
most trials, however these should be viewed with caution
due to their poor methodological quality [35]. A critical
review of rehabilitation in RA similarly noted hydrother-
apy to be effective, but concluded that many areas of
rheumatology rehabilitation, including hydrotherapy,
require more well-designed clinical trials to assess their
effect more comprehensively [36]. The EULAR recom-
mendations for the management of early arthritis support
the use of hydrotherapy as a treatment adjunct to phar-
macological interventions, but found insufficient evi-
dence to support a strong recommendation [30]. In
summary of the available evidence, there appears to be
some positive findings to support the use of hydrother-
apy, or water-based exercise, for individuals with RA. To
date, there is no evidence available examining the value
of hydrotherapy for individuals with RA taking anti-
TNFa therapy medication.
In summary, there is evidence to support the benefits
of gym and water based exercise therapy for individuals
with RA, however there is no evidence evaluating these
interventions for individuals with RA taking anti-TNFa
medication. There is evidence to suggest that regular
exercise induces anti-inflammatory effects, suggesting
that physical activity per se may suppress systemic low-
grade inflammation [37]. Although it has been estab-
lished that anti-TNF therapy improves insulin resistance
in RA, it does not seem to reverse rheumatoid cachexia
[9], however it does appear that anti-TNFa therapy
halts the progression of muscle deterioration. Therefore,
the combination of improved muscle capacity and anti-
TNFa therapy may lead to an enhanced benefit in terms
of exercise participation over and above that seen in
individuals with RA not taking this medication. Consid-
ering the evidence that has been presented supporting
the value of exercise for individuals with RA, the addi-
tion of anti-TNFa may enhance the effectiveness of
exercise prescription. By means of a RCT this study will
examine the value of a prescribed gym or water based
exercise programme for individuals with RA taking anti-
TNFa therapy medication when compared to a control
group of similar individuals receiving no exercise
intervention.
Methods/Design
Aim
The primary aim of this study is to examine the value of
group exercise therapy for individuals with RA on anti-
TNFa therapy medication. The value of land-based
exercise will be compared to a control group, and the
value of water-based exercise will be compared to a con-
trol group. The outcome of this study will be assessed in
terms of functional ability, pain, fatigue and quality of
life (QoL). Figure 1 shows the flow of participants
through the study. The secondary aim of this study is to
examine predictors (age, time period since diagnosis and
time period on anti-TNFa therapy medication) of out-
come of the Stanford Health Assessment Questionnaire
Disability Index (HAQ-DI) at 8 and 24 weeks.
Study design
A multicenter randomised controlled three-armed study
will be conducted to compare the effects of group exer-
cise (on land or in a hydrotherapy pool), to a group of
participants receiving no intervention.
Null hypothesis
People with RA taking anti-TNFa therapy medication
who participate in dynamic group exercise on land or in
water, will not demonstrate differences in functional
ability, pain, fatigue or quality of life, when compared to
a control group of individuals with RA taking anti-
TNFa therapy medication who do not participate in
dynamic group exercise on land or in water.
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People with RA taking anti-TNFa therapy medication
who participate in dynamic group exercise on land or in
water, will demonstrate differences in functional ability,
pain, fatigue or quality of life, when compared to a con-
trol group of individuals with RA taking anti-TNFa
therapy medication who do not participate in dynamic
group exercise on land or in water.
Ethical issues
Ethical approval has been granted for this study by the
St. Vincent’s Healthcare Group Ethics and Medical
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Figure 1 The flow of participants through the study.
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have been obtained for use of the Euroqol questionnaire
in this clinical trial. This trial is registered with Clinical-
Trials.gov (a service of the United States National Insti-
tutes of Health) identifier: NCT00855322.
Study participants
A sample of people with RA taking anti-TNFa therapy
medication will be recruited from a rheumatology ser-
vice based in two hospitals in Dublin, Ireland.
Inclusion criteria:
￿ Consenting male and females, aged 18 - 70 years
￿ Documented diagnosis of RA as classified by the
American College of Rheumatology (ACR) criteria
￿ Receiving anti-TNFa therapy medication for more
than three months
￿ ACR functional class I, II, III
￿ Willing to exercise bi-weekly on a fixed schedule
￿ Living within a 50 km radius of both recruiting
hospitals
Exclusion criteria:
￿ Physiotherapy in the previous three months
￿ Intra-articular corticosteroid injection within the
previous four weeks
￿ Joint surgery in the previous six months
￿ Unable to understand the concepts, assessments
and treatments that would be involved
￿ Contraindications to exercise therapy or
hydrotherapy
The flow of participants through the study is pre-
sented in figure 1.
Recruitment procedure
Possible participants will be sourced by the principal
investigators (AR and AB) from a computer database of
people who are currently taking anti-TNFa therapy med-
ication and who attend a rheumatology service based in
two hospitals in Dublin, Ireland. This computer database
is held in St, Vincent’s University Hospital. All indivi-
duals on this database, aged between 18 and 70 years,
who are taking anti-TNFa therapy medication for greater
than three months and who live within a 50 km radius of
the recruiting hospitals, will be invited by mail to partici-
pate. A follow-up telephone call will screen for major
exclusion criteria and give a detailed explanation of the
study. An information leaflet/consent form will then be
posted to prospective participants, where they will be
asked to consider the information and give informed,
written consent should they wish to participate.
Randomisation
Participants will be randomised in predetermined block
sizes by means of an allocation sequence generated using
a random number table devised by a statistician using
SAS software. Sealed opaque envelopes containing letters
indicating group assignment will be prepared in advance
using the allocation sequence. The envelopes will be
drawn by an independent person not involved in the con-
duct of the study. Baseline assessments will be carried out
by an investigator who is unaware of the allocation
sequence. Following assessment, participants will be
issued an envelope indicating their group allocation:
Group1 - Land-based exercise
Group 2 - Water-based exercise.
Group 3 - Control group, no intervention
Blinding
Baseline demographics and measures of treatment out-
come at baseline, eight weeks and 24 weeks will be col-
lected by an independent assessor who is not involved in
the trial and who is blinded to group allocation. Due to
the nature of the exercise interventions, participants and
physiotherapists conducting the exercise classes will not
be blinded to treatment allocation. The primary outcome
and some of the secondary outcomes, involve self-reported
questionnaires being completed by participants thus pre-
cluding blinding of assessment. Participants will be asked
not to divulge group allocation to the blind assessor.
Intervention
The land- and water-based exercise groups will be
supervised by the two principal investigators (AR and
AB). Qualitative methods were used to determine the
content and format of these exercise interventions.
Interview questions were formulated to examine current
expert opinion in relation to best practice. Thirteen
semi-structured interviews were conducted with senior
physiotherapists experienced in the areas of rheumatol-
ogy and hydrotherapy. Interviews explored their expert
opinions in relation to best practice. All interviews were
recorded using digital recording equipment. The inter-
views were transcribed verbatim and analysed for emer-
gent themes by means of a ‘grounded theory’ approach.
Based on the results of the analysis of these interviews,
appropriate gym and hydrotherapy programmes were
devised. The exercise programmes were in keeping with
EULAR’s recommendations of dynamic exercise for the
management of RA.
Gym Exercise Group Intervention
￿ Participants will attend a one hour group exercise
class, twice a week for 8 weeks. This will be held in
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tion unit, Dublin, Ireland.
￿ The class will commence with 10 minutes of group
warm-up exercises
￿ This is followed by 40 minutes of circuit-based
upper/lower limb strengthening and aerobic exer-
cises (10 stations lasting 4 minutes each)
￿ The class will finish with 10 minutes of cool-down
exercises.
The format and content of the gym exercise interven-
tion is detailed in Table 1.
Hydrotherapy Exercise Group Intervention
￿ Participants will attend a one hour group exercise
class, twice weekly for 8 weeks. The class will be
held in the hydrotherapy pool of a rheumatology
rehabilitation unit, Dublin, Ireland.
￿ The class will commence with 10 minutes of group
warm-up exercises.
￿ This will be followed by 30 minutes of group-based
upper limb, lower limb and trunk flexibility/
strengthening exercises. An aerobic exercise compo-
nent lasting 15 minutes (5 stations lasting 3 minutes
each) is circuit based.
￿ The class will finish with 5 minutes of cool-down
exercises.
The format and content of the water-based exercise
intervention is detailed in Table 2.
Control Group
￿ Participants will receive no intervention. They will
be asked not to alter their exercise habits for the
duration of the study.
Outcome measures
At the baseline assessment, demographic information
will be collected including age, gender, length of diagno-
sis, length of time taking anti-TNFa medication and
exercise history. The assessor administering the out-
comes will be blinded to participants’ group allocation,
and the same assessor will administer the outcomes at
baseline, eight weeks and 24 weeks.
Primary outcome measure
￿ The Stanford Health Assessment Questionnaire
Disability Index (HAQ-DI)
Secondary outcome measures
￿ Pain visual analogue scale- VAS
￿ Multidimensional Assessment of Fatigue- MAF
￿ Timed Chair Stand Test
￿ Grip Ability Test- GAT
￿ Fifty Foot Walk Test
￿ International Physical Activity Questionnaire-
IPAQ short “last 7 d”
￿ Euroqol- EQ-5D
￿ Qualitative Interviews at 8 and 24 weeks
The Stanford Health Assessment Questionnaire Dis-
ability Index (HAQ-DI) The HAQ-DI is the most
widely used functional measure in rheumatology [38]. It
was specifically developed for adults with arthritis [39].
Available evidence indicates that the HAQ-DI is feasible,
reliable, valid and sensitive to change in clinical trials in
RA [38].
It is a self-reported questionnaire and there are 20
items covering 8 categories. The categories are: dressing
and grooming, arising, eating, walking, personal hygiene,
reaching, gripping and other activities. Each item is
rated from 0 to 3, with 0 = no difficulty, 1 = some
Table 1 Content of the land-based (gym) exercise group
Duration/no. of
repetitions
Exercises
Warm
up
5-10 mins ￿ Walking forwards, backwards, sideways
￿ Joint ROM*- neck rotation/side flexion, shoulder rolls/hands behind back+ neck/shoulder abduction, elbow
flexion/extension, wrist flexion/extension, trunk rotation/side flexion, hip flexion, ankle rotation
￿ Stretches- Quad, Gastroc, Tricep, Posterior shoulder (10-15 sec hold each), latissimus dorsi stretch in supine
lying
Circuit 4 mins each station ￿ Station 1 = Upper limb free weights (shoulder elevation, biceps curl)
￿ Station 2 = Upper limb (wall press up, throwing ball against wall)
￿ Station 3 = Lower limb (sit to stand, hip extension in prone lie)
￿ Station 4 = Lower limb (single leg stands, squats)
￿ Station 5 = Trunk (on all fours-arm/leg lifts, supine lie- leg slides)
￿ Station 6 = Trunk ( supine lie-bridging, side lie- oyster exercise)
￿ Station 7 = Aerobic (Stationary bike)
￿ Station 8 = Aerobic (Walking as fast as possible)
￿ Station 9 = Aerobic (Jogging on trampette)
￿ Station 10 = Aerobic (Step ups)
Cool
down
5-10 mins ￿ Walking forwards/backwards, high stepping
￿ Posterior shoulder stretch (20 sec hold), shoulder rolls
￿ Quads, Gastroc, Hamstring stretch (20 sec hold)
￿ Spinal rotation, deep breathing exercises
*ROM = range of movement.
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highest score within a category is used as the category
score. If physical assistance or equipment is required the
category score is increased to 2. The mean of the 8 cate-
gories is used to calculate the HAQ-DI score. Scores
range from 0 to 3, with 0 indicating no functional dis-
ability and 3 indicating severe disability.
Pain Visual Analogue Scale (VAS) This is a self-
reported measure of pain severity. The pain VAS has
been found to be valid, reliable and sensitive to change
in non-drug clinical trials [40,41]. The scale consists of
a 100 millimeter horizontal line that is anchored with
verbal descriptors of “no pain” and “pain as bad as
could it be” [41]. Respondents are asked to place a line
perpendicular to the VAS line at the point that best
indicates their pain at the present time.
Multidimensional Assessment of Fatigue (MAF) The
MAF is an RA-specific revision of the Piper Fatigue
scale. Reasonable evidence of validation (14) and relia-
bility [42,43] has been identified for the MAF. Sensitivity
to change is shown following exercise [23]. It is a self-
administered questionnaire comprising 16 questions. It
measures 4 dimensions of self-reported fatigue: degree
and severity, amount of distress it causes, its timing
(how often it occurs and if it changed over the past
week), and the degree to which it interferes with
activities of daily living. Questions 1-15 form the final
score (Global Fatigue Index, 0-50) while question 16
concerns change over the past week.
T i m e dC h a i rS t a n dT e s tThis is an objective measure
of lower body strength, which is considered an indicator
of functional status. It has been found to be a reason-
able, reliable and valid indicator of lower body strength
in generally active, community-based older adults [44].
Timed chair stand tests are found to be simple, repro-
d u c i b l ea n dv a l i df o ru s ei na nR Ap o p u l a t i o n[ 4 5 ] .T h e
test is performed by counting the number of times an
individual can stand up and sit down in 30 seconds.
Grip Ability Test (GAT) This is a simple and rapid test
of hand function. It was developed to evaluate hand
function of people with RA [46]. The GAT is valid, reli-
able and sensitive to change [47]. The test consists of 3
tasks- putting a sock over one hand, putting a paper
clip on an envelope and pouring water from a jug. Each
task is timed and the GAT score is calculated as the
sum of the weighted time for each task. A GAT score
less than 20 seconds is considered normal. A high GAT
score indicates decreased hand function.
Fifty Foot Walk Test The 50 ft walk test is a measure
of function and it is widely used in rheumatological clin-
ical studies. It has established validity and reliability [48].
Fifty feet is marked on a flat straight floor. Participants
Table 2 Content of the water-based (hydrotherapy) exercise group
Duration/no. of repetitions Exercise
Warm up 5 mins ￿ Walking forwards/backwards/sideways
￿ Jogging on spot, kicking heels to buttocks
￿ Jumping jacks, stride jumping
￿ Joint ROM*- neck rotation/side flexion, shoulder rolls, wrist/hand ROM, trunk rotation
Upper limb 10-20 reps ￿ BE* shoulder horizontal ab/adduction
￿ BE shoulder glides into abduction
￿ BE shoulder pro/retraction ( elbow flexion/extension) and BE shoulder extension
￿ BA* shoulder stretch at wall into abduction and flexion (30 secs hold x 2 reps)
￿ TR* shoulder flexion/extension, ab/adduction, horizontal ab/adduction
￿ TR elbow flexion/extension
Encouraging scapular stability and trunk stability with all upper limb exercises
Lower limb 10-20 reps ￿ BA hamstring stretch (30 secs hold x 2)
￿ BA hip adductor/flexor stretch (30 sec hold × 2)
￿ TR hip flexion/extension, ab/adduction
￿ TR knee flexion/extension
￿ Single leg cycling
Encouraging trunk stability with all lower limb exercises
Back 10 reps ￿ Hanging on wall- Lumbar flexion, extension, rotation, side flexion
￿ Standing at wall- Trunk flexion/extension
￿ Transversus abdominus contraction while pushing float under water
Aerobic 10-15 mins (circuit - 5 stations × 2-3 mins) ￿ Station 1 = Aqua-jogging with running belt
￿ Station 2 = Step ups
￿ Station 3 = Jogging lengths of pool
￿ Station 4 = Cycling lengths of pool sitting on woggle
￿ Station 5 = Jogging on spot
Cool down 5 mins ￿ Walking forwards/backwards/sideways
￿ Posterior shoulder stretch and tricep stretch (30 sec hold x 2)
￿ Quads stretch (30 sec hold × 2)
￿ Hip adductor stretch in standing- transfer weight
*ROM = range of movement, BE= buoyancy eliminated, B A = buoyancy assisted, BR = buoyancy resisted, TR= turbulence resisted.
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marked area so that stride is established prior to reach-
ing the designated starting point. The participant is
instructed to walk at their fastest pace/speed. It is mea-
sured in seconds using a stopwatch, to one hundredth
of a second.
International Physical Activity Questionnaire (IPAQ)
short “last 7 d” The IPAQ short “last 7 d” is a self-
reported measure of physical activity. It has established
validity and reliability in an adult population [49]. The 9
items in the questionnaire provide information on the
time spent walking, in vigorous- and moderate-intensity
activity and in sedentary activity. The data gathered is
used to estimate total weekly physical activity by weight-
ing the reported minutes per week within each activity
category by a Metabolic Equivalent of Task (MET) energy
expenditure estimate assigned to each category. The
weighted MET-minutes per week (MET
.min
.wk
-1) are cal-
culated as duration x frequency per week x MET inten-
sity of each activity category, which are then summed.
Euroqol (EQ-5D) This is a generic health status instru-
ment designed to capture information on the overall
health-related quality of life (QoL) for individuals [50].
The EQ-5D is widely used in clinical trials and has been
found to be valid and reliable [51]. It consists of a ques-
tionnaire and a visual analogue scale (VAS). The ques-
tionnaire evaluates QoL in 5 dimensions - mobility, self
care, usual activity, pain/discomfort and anxiety/depres-
sion. Each dimension is divided into 3 levels - no pro-
blem, some problem and extreme problem. A weighted
index is used to calculate a score from 0 to 1, with 0
indicating full health and 1 indicating death. The VAS is
used to evaluate a person’s perception of their health
state. It is scored on a scale where 0 represents the worst
and 100 represents the best imaginable health state.
Qualitative Interviews In the region of 50% of the
exercise participants will be interviewed at 8 weeks to
ascertain their perceptions of the exercise interventions.
Semi-structured interviews will be conducted and
recorded. They will be transcribed verbatim and ana-
lysed for emergent themes using a grounded theory
approach. This affords an opportunity to capture the
participants’ opinion regarding their perceived benefit,
satisfaction and potential compliance for continuing to
attend a similar programme if available locally.
All participants who received an exercise intervention
will also take part in a semi-structured interview at 24
weeks. This is to determine whether they continued to
exercise following completion of the 8 week exercise pro-
gramme. Potential barriers to exercise will be explored.
Sample size considerations
The primary outcome measure (HAQ-DI) was used to
calculate the sample size required. It is a widely used
measure of function in rheumatological clinical trials.
Previous work by Kosinski et al determined a reduction
of 0.19 to be a minimally important change in the HAQ
score [52] (range 0-3). Based on a two-group compari-
son, power calculations [53] indicated that a minimum
of 171 participants per group are required to detect a
reduction of 0.19 in the HAQ-DI at a two-sided signifi-
cance level of 5% and a power of 80%, assuming a stan-
dard deviation of 0.63 [54]. Therefore, for this three-
armed study a total of 513 participants are required. To
compensate for a possible drop-out rate of 20% and to
a l l o wt h es a m p l es i z eb ed i v i s i b l eb yt h r e e ,at o t a ls a m -
ple size of 618 people is considered appropriate.
Statistical analysis
The statistical analysis will be performed in consultation
with a statistician. Statistical Package for the Social
Sciences (SPSS 16) will be used to undertake the analy-
sis. Baseline and demographic data will be presented
using descriptive statistics. Differences from baseline will
be calculated for all primary and secondary outcomes.
Mean differences, standard deviations and 95% confi-
dence intervals will be calculated for all continuous vari-
ables. Data will be analysed on an ‘intention to treat
basis’ that is, all participants will be analysed in the
groups to which they are randomised, whether or not
they complete the intervention. Missing data will be
estimated in SPSS by means of multiple imputation with
a regression method.
For the primary endpoint (HAQ-DI at 8 and 24
weeks) an analysis of covariance (ANCOVA) will be
used to explore between group differences in terms of
the continuous variables thereby accounting for baseline
scores. A preliminary examination of the data will be
undertaken to ensure there is no violation of the
assumptions associated with ANCOVAs. An ANCOVA
adjusts each subject’s follow-up score for his or her
baseline score but has the advantage of being unaffected
by baseline differences [55]. The fixed factor will be the
group to which the participants were randomised while
the covariates will be the baseline measures of the con-
tinuous outcome measures. The dependent variables will
be the continuous outcome measures at 8 and 24 weeks.
For secondary outcomes, if the data is not normally dis-
tributed or is categorical, the adequate tests will be
employed. A significance level of 0.05 will be set for any
inferential statistics conducted.
Multiple regression analysis will be used for secondary
analysis in order to examine predictors of outcome at 8
and 24 weeks. A number of predictor variables age, time
period since diagnosis and time period on anti-TNFa
medication will be examined. The dependent variable
will be dichotomous in terms of change in the HAQ
(0 = change less than 0.1, 1 = change greater than or
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the gym and hydrotherapy groups. All predictor vari-
ables will be examined for collinearity. Univariate logis-
tic regression will be performed on all predictors
thought to be associated with outcome. Those shown to
be associated will be entered into the multivariate logis-
tic regression model and backward regression will be
performed. Variables with the lowest predictive value
will be removed from the model if p > 0.05. Ninety five
percent confidence intervals will be calculated for all
final predictors.
Conclusion
We have presented the rational and design of a rando-
mized controlled trial to investigate the effects of parti-
cipating in group exercise (on land or in water) for
people with RA on anti-TNFa therapy medication, com-
pared to non-participation. Current Irish Health Strategy
proposes the provision of health services in health facil-
ities and local communities all over Ireland. These types
of exercise groups, if shown to be beneficial, are ideally
suited for delivery in community settings. Treating indi-
viduals in the community will lessen the reliance on
specialist services and the hospital system. This could
lead to better outcomes, better health status and better
cost effectiveness.
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